Prostate Specific Antigen antibody
Quick Overview for Prostate Specific Antigen antibody (ABIN3026041)
Target
See all Prostate Specific Antigen (PSA) AntibodiesReactivity
Host
Clonality
Conjugate
Application
Clone
-
-
Purification
- Protein G affinity chromatography
-
Immunogen
- PSA (p30) from human sperm plasma was used as the immunogen for the Prostate Specific Antigen antibody.
-
Isotype
- IgG1 kappa
-
-
-
-
Application Notes
-
Optimal dilution of the Prostate Specific Antigen antibody should be determined by the researcher.
1. Staining of formalin-fixed tissues requires boiling tissue sections in 10 mM Citrate buffer, pH 6.0, for 10-20 min followed by cooling at RT for 20 minutes
2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.\. Flow Cytometry: 0.5-1 μg/million cells in 0.1ml,Immunofluorescence: 0.5-1 μg/mL,Immunohistochemistry (FFPE): 0.5-1 μg/mL for 30 min at RT (1),Prediluted format : incubate for 30 min at RT (2) -
Restrictions
- For Research Use only
-
-
-
Concentration
- 1 mg/mL
-
Buffer
- 1 mg/mL in 1X PBS, BSA free, sodium azide free
-
Preservative
- Azide free
-
Storage
- 4 °C,-20 °C
-
Storage Comment
- Store the Prostate Specific Antigen antibody at 2-8°C (with azide) or aliquot and store at -20°C or colder (without azide).
-
-
- Prostate Specific Antigen (PSA)
-
Alternative Name
- Prostate Specific Antigen
-
Background
- Recognizes a single protein of 33-34 kDa, identified as the prostate specific antigen (PSA). This mAb is highly specific to PSA and stains prostatic secretory and ductal epithelium in both normal and neoplastic tissues. PSA is a chymotrypsin-like serine protease (kallikrein family) exclusively produced by the prostate epithelium, and abundant in seminal fluid. PSA can be detected in the sera of patients with prostatic carcinoma. It is predominantly complexed to a liver-derived serine protease inhibitor, alpha-1-antichymotrypsin (ACT). A higher proportion of serum PSA is complexed to ACT in prostate cancer than in benign prostate hyperplasia. This mAb makes an excellent pair with mAb A67-B/E3 for PSA tests.
-
Pathways
- Complement System
Target
-